« Back
Home /
Lenalidomide

Lenalidomide

Item no.	HY-A0003-5g
Manufacturer	MedChem Express
CASRN	191732-72-6
Amount	5 g
Quantity options	100 mg 10mM/1mL 1 g 500 mg 5 g
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Neural Development Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	ACS Omega. 2024 Dec 3;9(50):49739-49748. ACS Pharmacol Transl Sci. 2021 Feb 26. Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254. Am J Pathol. 2015 Jun;185(6):1783-94. Biochim Biophys Acta Mol Basis Dis. 2022 Jun 22;166472. bioRxiv. 2024 June 12. bioRxiv. 2024 October 19. bioRxiv. April. Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5. Cancer Res. 2024 Oct 22. Cancer Sci. 2019 Dec;110(12):3802-3810. Cancers (Basel). 2024 Mar 28, 16(7), 1319. Cell Rep Med. 2024 Mar 19;5(3):101472. Cell Rep Methods. 2023 Oct 23;3(10):100599. Cell Rep. 2024 May 8;43(5):114211. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Cell. 2018 Sep 20;175(1):171-185.e25. Clin Chim Acta. 2023 Dec 14:117707. Elife. 2018 Aug 1;7:e38430. Exp Cell Res. 2020 Aug 1;393(1):112054. Faculty of Science, Masaryk University. Department of Experimental Biology.2014. Food Chem Toxicol. 2019 Mar;125:392-402. Free Radic Biol Med. 2023 Apr 10;S0891-5849(23)00373-8. Front Cell Infect Microbiol. 2022 Jul 28;12:954814. Harvard Medical School LINCS LIBRARY Inflammation. 2019 Feb;42(1):221-234. Int J Mol Sci. 2023 Sep 14, 24(18), 14097. iScience. 19 July 2022, 104781. J Transl Med. 2024 Dec 3;22(1):1095. Leukemia. 2025 Jan 30. Microbiome. 2025 Feb 28;13(1):56. Mol Ther Oncol. 2025 Feb 20;33(1):200952. Nat Cancer. 2022 May;3(5):595-613. Nat Chem Biol. 2021 Jun;17(6):711-717. Nat Commun. 2017 May 22;8:15398. Nature. 2024 Sep;633(8030):670-677. Oncol Rep. 2018 Jun;39(6):2873-2880. Oxid Med Cell Longev. 29 Dec 2021. Patent. US20170360780A1. Patent. US20180263995A1. Patent. US20210379039A1. Patent. US20220332776A1. Patent. US20240261246A1. Universidad de Navarra. 2024 Feb 28. University of Washington. The Columbian College of Arts and Sciences. August 31, 2021. Food Chem Toxicol. 2019 Mar;125:392-402. [6]Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1. [7]Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3(7):e941742. [1]Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309. [2]Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36. [3]Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. [4]Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82. [5]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.
Smiles	O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CC-5013
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Ligands for E3 Ligase; Molecular Glues
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	259.26
Product Description	Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; PROTAC
Isoform	Cereblon
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-A0003-5g-safety-datasheet.pdf